NAMS — NEWAMSTERDAM PHARMA COMPANY

Ownership history in OMERS ADMINISTRATION Corp  ·  3 quarters on record

This page tracks every 13F SEC filing in which OMERS ADMINISTRATION Corp reported a position in NEWAMSTERDAM PHARMA COMPANY (NAMS). Data includes quarterly share count, position size as % of portfolio, estimated market value, and end-of-quarter stock price — sourced directly from SEC EDGAR 13F filings.

Peak position
0.01% (2025 Q1)
Avg. % of fund
0.0%
First filed
2024 Q4
Last filed
2025 Q3
Quarters held
3
Quarter Action Shares Change Chg % % of Fund Mkt Value Price (EOQ)
2025 Q3 REDUCED 13,900 -23,800 -63.1% 0.00% $395K $28.44
2025 Q1 ADDED 37,700 +17,200 +83.9% 0.01% $772K $20.47
2024 Q4 INITIATED 20,500 — — 0.00% $527K $25.70
% of Fund (quarterly)    NAMS price (monthly, adj. close)

Other funds also holding NAMS

As of 2025 Q4 — sorted by position size

FCPM III SERVICES B.V. 42.3% Bain Capital Life Sciences Investors, LLC 3Y 7Y 19.63% Frazier Life Sciences Management, L.P. 3Y 15.96% Medicxi Ventures Management (Jersey) Ltd 3Y 12.06% First Turn Management, LLC 3.58% RA CAPITAL MANAGEMENT, L.P. 3Y 7Y 3.43% Decheng Capital LLC 2.79% Artia Global Partners LP 3Y 2.5% Duquesne Family Office LLC 3Y 7Y 2.4% Atle Fund Management AB 3Y 7Y 2.21%
← Back to OMERS ADMINISTRATION Corp Holdings